Skip to content

New study suggests that transparency amongst industry-sponsored clinical trials is improving

A study from the Association of the British Pharmaceutical Industry (ABPI) published this week in the peer-review journal Current Medical Research and Opinion (CMRO) suggests that transparency amongst industry-sponsored clinical trials is continuing to improve, with results of 90% of trials on all new medicines approved by the European Medicines Authority (EMA) in 2012 disclosed within a 12-month timeframe.

Key findings of the study show that of the 340 industry-sponsored trials (completed before the end of January 2014) associated with all 23 new medicines approved by the EMA in 2012:

  • 307 or 90% had results disclosed on a registry or in scientific literature within 12 months of first regulatory approval or trial completion, and
  • 312 or 92% had results disclosed by the end of the study at 31 July 2014

A press release from the ABPI about this study can be found here.

Aspire Scientific Ltd View All

Ryan co-runs Aspire Scientific, a dynamic, forward-thinking medical writing agency. Ryan has a passion for innovation, science and ethical communication.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: